The immuno-oncology company, based on University of Turin research, has completed a $21m series B round led by Claris Ventures.

Neophore, a UK-based immuno-oncology treatment developer established by University of Cambridge’s biopharmaceutical spinout PhoreMost, closed a £15.2m ($21m) series B round yesterday led by Claris Ventures.

Astellas Venture Management, the corporate venturing arm of pharmaceutical firm Astellas, also contributed to the round, as did CRT Pioneer Fund, 2Invest and 3B Future Health Fund.

Neophore was spun out of PhoreMost in 2017 to commercialise research conducted by Alberto Bardelli and Giovanni Germano at University of Turin, and is working on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.